North America Bioreactors Market Drivers and Forecasts by 2027

The North Americabioreactors marketis expected to reach US$ 2,102.75 Mn by 2027 from US$ 1,188.50 Mn in 2019; the market is estimated to grow at a CAGR of 7.5%during 2020–2027.

The increasing adoption of single-use bioreactors and rapidly growing demand for bioreactors from biopharmaceutical and biotechnology industries are among the major factors driving the growth of the market in North America. However, stringent regulatory frameworks in different countriesrestrain the North America Bioreactors market growth to a certain extent.

A bioreactor is equipment or system engineered to provide biologically active environment for the production of various medical and pharmaceutical compounds. The vessel is used to carry out a chemical process, which involves organisms or biochemically active substances derived from such organisms. This process can either be aerobic or anaerobic. The bioreactors are commonly cylindrical, ranging in size from liters to cubic meters, and are generally made of stainless steel. Bioreactors provide a controllable environment, in terms of pH, temperature, nutrient supply, and shear stress for any cells.

The pharmaceutical industry has been growing at an unprecedented pace in recent years. The strong demand for biologics and biosimilars has driven the growth of the industry. The biopharmaceuticals industry is one of the most significant contributors to the economy of many countries. The US is the largest market for biopharmaceuticals and leader in biopharmaceutical R&D. As per the Pharmaceutical Research and Manufacturers Association (PhRMA), the US firms conduct over half the world's total pharmaceutical R&D (worth US$ 75 billion) and hold the highest number of patents in new medicines. The increasing number of biologics approvals, growing pipeline of biosimilars, and mounting investments in research activities are prime factors facilitating the growth of the industry.

Advancements in the field of bioreactors have opened many opportunities for the bioreactor market players. Leading players have been coming up with innovative products since the last few years. The improvements in bioreactors aid in the faster and easier production of biopharmaceuticals at reduced production costs. For instance, Pall Corporation launched the mPath bioreactor control systemsthat provide accurate measurement and control of single-use process development-scale bioprocesses.

Presently, various biopharma companies, research institutes, and pharmaceutical and biotech companies are engaged in conducting collaborative work to address the global issue of COVID-19 outbreak. This has eventually shifted their focus from new drugdevelopment to vaccine development against this virus strain. However, the diversion of resources from liposome-based drugs development to COVID-19 therapeutics and ventilators, among others, is likely to hamper overall productivity of the drug development industries in the next few years. However, exceptthe manufacturing and sales operations in the bioreactors industry,theutilization of bioreactors, have tremendously increased. For instance, researchers in California are using the bioreactors to analyze the activities of virus, which might assist them in vaccine discovery. These factors are projected to drive the adoption of bioreactors during post-pandemic period in North America.

Mexico Bioreactors Market,Revenue and Forecast to 2027 (US$Mn)

NORTH AMERICABIOREACTORS MARKET SEGMENTATION

By Cell

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Others

By Molecule

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Stem Cells
• Gene Therapy
• Others

By Technology

• Wave-Induced Motion SUB
• Stirred SUB
• Single-Use Bubble Column
• Others

By Country

• US
• Canada
• Mexico

Companies Mentioned

• Thermo Fisher Scientific Inc
• Pall Corporation
• PBS Biotech,Inc
• General Electric Company
• MERCK KGaA

North America Bioreactors Report Scope